MLNMA.PA Nicolas Miguet et Associes EURONEXT 18 Mar 2026 +21.95%: watch volume

The MLNMA.PA stock surged to €0.10, rising 21.95% on 18 Mar 2026 as volume spiked to 11,462 shares. This move pushed the share price above its 50-day average of €0.08 and 200-day average of €0.07 on EURONEXT in Europe. Traders showed heavy interest with a relative volume of 6.73 versus the 1,702 average. We focus on why the jump matters, how valuation and technicals look, and what Meyka AI’s short-term forecast implies for follow-through.

MLNMA.PA stock quick take

Price action is the main fact: €0.10 close, +21.95%, volume 11,462. The stock traded at €0.10 all day with a prior close of €0.082. Market cap stands near €1.09M and shares outstanding are 10,900,800.

Volume surge and trading details

Liquidity drove the move: today’s volume was 11,462, well above the average 1,702. That gives a relative volume of 6.73, a clear high-volume mover signal on EURONEXT. High volume makes the price move more meaningful for short-term traders, but it can also reflect one-off flows or block trades.

Fundamentals and valuation

Nicolas Miguet et Associes shows weak earnings but reasonable book backing. EPS is -0.156 and PE is negative at -0.64, reflecting a recent loss. Price to book sits near 1.02, with cash per share at €0.08 and book value per share €0.09. Net margins are negative, and return on equity is -7.27%, so core profitability remains a key risk.

Technicals, trend signals and Meyka AI grade

Technicals are mixed but the trend strength is notable. RSI is 44.30, ADX reads 46.38 indicating a strong directional move. Bollinger Bands show a tight range with upper €0.11 and lower €0.08.

Meyka AI rates MLNMA.PA with a score out of 100: 58.71 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs only; they are not guaranteed and we are not financial advisors.

Price forecasts and analyst-style targets

Meyka AI’s forecast model projects monthly €0.11 and quarterly €0.05. Compared to the current €0.10, the monthly figure implies +10.00% upside while the quarterly figure implies -50.00% downside. For practical targets, we frame a short-term base target of €0.12, a cautious 12-month target of €0.06, and a high-case target near the 52-week high €0.19. Forecasts are model-based projections and not guarantees.

Catalysts, sector context and risks

Key catalysts would include improved earnings, new product or service disclosures, or insider buying. The company sits in Financial Services, industry Financial – Data & Stock Exchanges, where peers show stronger profitability. Risks include persistent losses, low liquidity outside spikes, and negative margins. Recent media links show comparative data listings but no company-specific press releases today source source.

Final Thoughts

MLNMA.PA stock closed at €0.10 on EURONEXT on 18 Mar 2026 after a 21.95% move on unusually high volume. That spike signals genuine trader interest, but fundamentals remain weak with EPS -0.156, negative margins, and limited market cap €1.09M. Meyka AI’s forecast model projects monthly €0.11, which implies +10.00% from the current price, while a quarterly projection of €0.05 implies -50.00%. Short-term traders may look for volume confirmation above 11,000 and hold points near €0.08. For longer-term investors, consider the company’s negative ROE and small free cash flow. Meyka AI, our AI-powered market analysis platform, flags MLNMA.PA as a C+ (HOLD) on score 58.71, advising careful position sizing. Our base case price target is €0.12, with a conservative 12-month scenario at €0.06 and a bull case to €0.19. Forecasts are model projections and not guarantees; confirm with company filings before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.